31907172
2020 Feb
Researchers may finally have identified a first-line treatment for hepatocellular carcinoma that is superior to the current standard. In a phase III trial, atezolizumab plus bevacizumab extended median progression-free survival and overall survival compared with sorafenib, and the combination was associated with a similar rate and severity of side effects as sorafenib.

